TG Therapeutics Investigational Trial Site
Tbilisi, Georgia
173 recruiting
Showing 1–9 of 9 trials
Recruiting
Phase 2
Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
Schizophrenia
TG Therapeutics, Inc.60 enrolled2 locationsNCT07680946
Recruiting
Phase 2Phase 3
Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
Relapsing Multiple Sclerosis
TG Therapeutics, Inc.240 enrolled2 locationsNCT07220252
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
Myasthenia Gravis
TG Therapeutics, Inc.120 enrolled2 locationsNCT07673744
Recruiting
Phase 1
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
B-cell Mediated Autoimmune Disorders
TG Therapeutics, Inc.100 enrolled8 locationsNCT06680037
Recruiting
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Multiple SclerosisRelapsing Multiple Sclerosis
TG Therapeutics, Inc.2,000 enrolled91 locationsNCT06433752
Recruiting
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
Relapsing Multiple Sclerosis
TG Therapeutics, Inc.16 enrolled5 locationsNCT06143514
Recruiting
Phase 2
A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)
Multiple Sclerosis
TG Therapeutics, Inc.350 enrolled39 locationsNCT07503873
Recruiting
Phase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Relapsing Multiple Sclerosis
TG Therapeutics, Inc.800 enrolled47 locationsNCT05877963
Recruiting
Phase 3
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)
Relapsing Multiple Sclerosis
TG Therapeutics, Inc.360 enrolled42 locationsNCT07211633